Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-Hodgkin's lymphoma

P J Bierman1, J O Armitage

  • 1University of Nebraska Medical Center, Omaha 68198-3330, USA.

Current Opinion in Hematology
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Intensifying therapy, including high-dose consolidation and transplantation, shows promise for improving outcomes in non-Hodgkin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripheral T-Cell Lymphoma-A Brief Review.

Leukemia & lymphoma·2016
Same author

Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma.

Expert opinion on biological therapy·2015
Same author

Factors affecting the development of atrial fibrillation and atrial flutter (AF/AFL) following autologous hematopoietic SCT (auto-HSCT).

Bone marrow transplantation·2012
Same author

Chromosomal abnormalities in malignant lymphoma and Hodgkin's disease.

Leukemia & lymphoma·2011
Same author

Optic neuropathy in patients with glioblastoma receiving bevacizumab.

Neurology·2009
Same author

The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Non-Hodgkin's lymphoma (NHL) treatment is evolving with a focus on intensified therapeutic strategies.
  • High-risk patients and those with relapsed disease represent key areas for therapeutic advancement.
  • Emerging therapies like radiolabeled antibodies and specific treatments for gastric MALT lymphoma are under investigation.

Purpose of the Study:

  • To review current and emerging treatment strategies for various types of non-Hodgkin's lymphoma.
  • To assess the evidence supporting intensified therapy, including high-dose consolidation and transplantation, in NHL.
  • To highlight areas of unmet need and ongoing research in NHL management.

Main Methods:

  • Review of current literature and clinical trial data on non-Hodgkin's lymphoma therapies.

Related Experiment Videos

  • Analysis of evidence for high-dose consolidation with autologous hematopoietic rescue in first remission.
  • Evaluation of data on transplantation for relapsed lymphoma and novel approaches like radiolabeled antibody therapy.

    • Main Results:

    • High-dose consolidation with autologous hematopoietic rescue improves survival in high-risk, first-remission patients.
    • Transplantation offers improved survival for relapsed patients compared to conventional chemotherapy.
    • Radiolabeled antibody therapy shows promising results in Phase II trials.
    • Gastric MALT lymphoma regression observed with Helicobacter pylori eradication, but long-term data is limited.
    • Mantle cell lymphoma and primary CNS lymphoma present management challenges with ongoing research.

    Conclusions:

    • Intensified therapy, including high-dose consolidation and transplantation, is a viable strategy for improving outcomes in specific non-Hodgkin's lymphoma populations.
    • Further research is needed for advanced low-grade lymphomas, mantle cell lymphoma, and primary CNS lymphoma.
    • Novel therapeutic approaches, such as radiolabeled antibodies and targeted eradication of H. pylori, warrant continued investigation.